Advanced search
Publication Cover
Scandinavian Journal of Infectious Diseases Volume 45, 2013 - Issue 5
Submit an article Journal homepage
148
Views
1
CrossRef citations to date
0
Altmetric
Rapid Communication

Efficacy, safety, and pharmacokinetics of once-daily boosted darunavir in pretreated HIV-infected patients

David ZucmanFrom the Foch Hospital, Suresnes
,
P. De TruchisRaymond-Poincaré Hospital, Garches
,
Gilles PeytavinBichat Claude Bernard Hospital, Paris
,
Diane DescampsBichat Claude Bernard Hospital, Paris
,
C. DuvivierAP-HP, Groupe Hospitalier Necker-Enfants Malades, Service de Maladies Infectieuses et Tropicales, Centre d’Infectiologie Necker-Pasteur, Université Descartes-Paris 5, Paris;Institut Pasteur, Centre Médical de l’Institut Pasteur, Centre d’Infectiologie Necker-Pasteur, Département Infection et Epidémiologie, Paris
,
L. TegnaGeorges Pompidou Hospital, Paris
,
Laurence WeissGeorges Pompidou Hospital, Paris
,
Jean L. DelassusRobert Ballanger Hospital, Aulnay-sous-Bois
,
A. BenalycherifInstitut de Médecine et d’Epidémiologie Appliquée (IMEA), Paris, France
&
Roland LandmanBichat Claude Bernard Hospital, Paris;Institut de Médecine et d’Epidémiologie Appliquée (IMEA), Paris, FranceCorrespondence[email protected]
 show all
Pages 407-410 | Received 13 Sep 2012, Accepted 15 Nov 2012, Published online: 11 Mar 2013

References

  • Tomaka F, Lefebvre E, Sekar V, Van Baelen B, Vangeneugden T, Vandevoorde A, et al. Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers. HIV Med 2009;10:318–27.
  • Madruga JV, Berger D, McMurchie M, Suter F, Banhegyi D, Ruxrungtham K, et al. Efficacy and safety of darunavir– ritonavir compared with that of lopinavir–ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 2007;370: 49–58.
  • Mills AM, Nelson M, Jayaweera D, Ruxrungtham K, Cassetti I, Girard PM, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS 2009;23:1679–88.
  • Clumeck N, Barnett BJ, Ive P, Hendrick A, Opsomer M, Van de Casteele T, Tomaka F. Long-term safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in ARTEMIS. USAPoster MOPE 169. IAS Conference, 2011.
  • Arribas JR, Iribarren JA, Knobel H, Ribera E, Rubio R, Viciana P, et al. Adherence, treatment satisfaction and effectiveness of once-daily (QD) vs twice-daily (BID) antiretroviral therapy (AT), in a large prospective observational cohort (CUVA Study). Abstract WePeB5780. 15th International Conference on AIDS, Bangkok, Thailand, July 2004.
  • De Meyer SM, Spinosa-Guzman S, Vangeneugden TJ, de Béthune MP, Miralles GD. Efficacy of once-daily darunavir/ritonavir 800/100 mg in HIV-infected, treatment-experienced patients with no baseline resistance-associated mutations to darunavir. J Acquir Immune Defic Syndr 2008;49:179–82.
  • Arribas JR, Horban A, Gerstoft J, Fätkenheuer G, Nelson M, Clumeck N, et al. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS 2010;24:223–30.
  • Sekar V, Vanden Abeele C, Van Baelen B, Vis P, Lavrays L, De Pauw M, et al. Pharmacokinetic/pharmacodynamic analyses of once-daily darunavir in the ARTEMIS study. Abstract 769. 15th Conference on AIDS and Opportunistic Infections, Boston, USA, February 2009.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.